DecisionRx Appoints Michael Tilton as Chief Growth Officer

DecisionRx Appoints Michael Tilton as Chief Growth Officer

By Karen Roman DecisionRx said it appointed Michael Tilton as Chief Growth Officer to lead the expansion of the company’s Medication Therapy Optimization platform. Tilton’s previous roles include senior vice president at Humana, as well as other senior leadership positions...

Aktis Oncology’s AKY-1189 Shows Potential in Targeting Cancers

Aktis Oncology’s AKY-1189 Shows Potential in Targeting Cancers

By Daniella Parra Aktis Oncology said AKY-1189 is showing promise to treat cancers such as metastatic urothelial carcinoma, breast, lung, colorectal and cervical cancers. The company said data from an oral plenary and two posters highlighted significant tumor uptake and...

Medera Starts Trial to Treat Heart Failure

Medera Starts Trial to Treat Heart Failure

By Karen Roman Biotechnology company Medera Inc. said it will start the Cohort B (high-dose) trial of SRD-002, the first-in-human cardiac gene therapy for Heart Failure with Preserved Ejection Fraction. The company finished Cohort A (low-dose) with favorable efficacy results after...

MOBILion Systems Redefines Complex Sample Analysis

MOBILion Systems Redefines Complex Sample Analysis

By Karen Roman MOBILion Systems, Inc. revealed its hi-res mass spectrometry functionality with implementations for proteomics, metabolomics and lipidomics, among others. The company’s approach is up to 5-10 times faster than current systems, close to 100% ion utilization efficiency and it...

CMR Surgical Receives FDA OK for Robot “Versius”

CMR Surgical Receives FDA OK for Robot “Versius”

By Karen Roman Global surgical robotics company CMR Surgical said the FDA has granted marketing authorization for its Versius Surgical Robotic System in the U.S.   Versius is the world’s second most utilized surgical robotic system with over 26,000 procedures...

SkylineDx to Present Data on Screening for Melanoma Patients

SkylineDx to Present Data on Screening for Melanoma Patients

By Karen Roman Diagnostics company SkylineDx said it will present clinical data on the success of its Merlin test at the 21st International Congress of the Society for Melanoma Research 2024 in New Orleans. The CP-GEP Merlin test accurately stratifies...

Eliem Therapeutics Changes Name to Climb Bio

Eliem Therapeutics Changes Name to Climb Bio

By Karen Roman Eliem Therapeutics, Inc. (Nasdaq: ELYM) said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol “CLYM” on Oct. 3. This rebranding reflects Climb’s laser-focused mission on...

Input your search keywords and press Enter.